Invention Grant
US09546366B2 Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
有权
复制因子C-40（RFC40 / RFC2）作为雌激素阳性和阴性和三阴性乳腺癌的预后标志物和靶标
- Patent Title: Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
- Patent Title (中): 复制因子C-40（RFC40 / RFC2）作为雌激素阳性和阴性和三阴性乳腺癌的预后标志物和靶标
-
Application No.: US14948896Application Date: 2015-11-23
-
Publication No.: US09546366B2Publication Date: 2017-01-17
- Inventor: Rakhee S. Gupte
- Applicant: Raadysan Biotech, Inc.
- Applicant Address: US NY Fishkill
- Assignee: Raadysan Biotech, Inc.
- Current Assignee: Raadysan Biotech, Inc.
- Current Assignee Address: US NY Fishkill
- Agency: Hodgson Russ LLP
- Main IPC: A61K48/00
- IPC: A61K48/00 ; C12N15/11 ; C07H21/02 ; C07H21/04 ; C12N15/113 ; C12Q1/68 ; G01N33/574
Abstract:
The present disclosure relates generally to cancer and particularly to breast cancer including estrogen sensitive, estrogen resistant and triple negative breast cancer (TNBC), and to methods of diagnosis and prognosis thereof and therapeutic intervention involving replication factor C 40 (RFC40). Methods and assays for evaluating breast cancer are provided. The disclosure also relates to inhibition or modulation of RFC40 in treatment or alleviation of cancer, including breast cancer. RFC40 inhibitors, including siRNAs, miRNAs, and shRNAs, which specifically affect cancer cells, particularly breast cancer cells, are provided.
Public/Granted literature
Information query
